Form 4: Biohaven CFO Reports Routine Share Vesting and Tax Withholding

Biohaven Ltd.'s Chief Financial Officer, Matthew Buten, reported the scheduled vesting of restricted share units and subsequent tax-related share withholding on January 5, 2026.

Summary

• Matthew Buten, Chief Financial Officer of Biohaven Ltd. (BHVN), reported transactions on January 5, 2026.
• He acquired 4,250 common shares through the vesting of restricted share units (RSUs) at a price of $0.
• Concurrently, 2,594 common shares were disposed of by the Issuer to satisfy tax withholding requirements related to the RSU vesting, at a price of $9.93 per share.
• Following these transactions, Mr. Buten beneficially owns 195,652 common shares directly and 8,500 derivative restricted share units.
• The common share balance includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025.
• The reported RSU vesting is part of an original grant of 17,000 units on January 5, 2025, vesting in four equal annual installments.

Sentiment

Score: 6

Explanation: The filing reports a routine, scheduled insider transaction related to executive compensation (RSU vesting and tax withholding). It does not indicate any significant positive or negative operational or financial developments for the company, hence a neutral-to-slightly positive sentiment reflecting continued executive commitment.

Positives

• Vesting of 4,250 restricted share units indicates continued employment and compensation for the Chief Financial Officer.
• The acquisition of shares through RSU vesting at a $0 price represents a non-cash compensation benefit.

Negatives

• 2,594 common shares were withheld by the Issuer to cover tax obligations, reducing the direct share count, which is a standard practice for RSU vesting.

Future Outlook

The remaining 8,500 restricted share units held by the CFO are scheduled to vest in two equal installments on January 5, 2027, and January 5, 2028, contingent on continued service.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation. It does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event. The tax withholding slightly reduces the CFO's direct ownership but is a standard practice.
• Employees: Reflects standard executive compensation practices, which may be consistent with broader employee incentive programs.

Next Steps

• Future vesting of 4,250 restricted share units on January 5, 2027.
• Future vesting of 4,250 restricted share units on January 5, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction involving the vesting of restricted share units and subsequent tax withholding. It provides no new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this a standard disclosure of executive compensation.

Keywords

Biohaven, BHVN, Form 4, insider transaction, Chief Financial Officer, Matthew Buten, restricted share units, RSU, share vesting, tax withholding, beneficial ownership, equity compensation